This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 681257 and to assess the efficacy of different doses and dosing regimens of ISIS 681257 for reduction of plasma Lipoprotein(a) \[Lp(a)\] levels in participants with hyperlipoproteinemia(a) and established cardiovascular disease (CVD).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percent Change From Baseline in Fasting Lipoprotein A [Lp(a)] at the Primary Analysis Time Point
Timeframe: Baseline and Month 6 (Week 25 for Cohorts A, B and C and Week 27 for Cohorts D and E)
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Timeframe: Up to 16 weeks post treatment period (up to approximately 1.3 years)
Number of Participants With TEAEs by Maximum Severity
Timeframe: Up to 16 weeks post treatment period (up to approximately 1.3 years)
Number of Participants With TEAEs Leading to Study Discontinuation
Timeframe: Up to 16 weeks post treatment period (up to approximately 1.3 years)